THE REMODELING OF LEFT ATRIUM AND VASODILATION FACTORS CHANGES IN ISCHEMIC HEART FAILURE
Keywords:heart remodeling factors of vasodilation, heart failure.
Background. According to the national registries of European countries and epidemiological studies, the prevalence of chronic heart failure (CHF) among adults is 2,0-5,0%, and increases due to age, in people aged over 70 years old it is 10,0-20,0%.
Objective. To find out the specific features of remodeling of the left atrium and change of vasodilation factors in ischemic heart failure with reduced and preserved left ventricular ejection fraction and to establish correlation relationships.
Methods. A full clinical examination of 153 patients with CHF (105 men and 48 women) was conducted to achieve this objective. The surveyed patients underwent clinical examinations; spectrophotometric parameters: quantification of markers of vasodilation, metabolites of monoxide nitrogen – nitrates and nitrites with Gris reagent; content of endothelial nitric oxide synthase (eNOS) in serum - ELISA for the set of Nitric Oxide Synthase 3, Endothelial (NOS3) Human ELISA Kit (Cloud-Clone Corp, USA). Electrocardiographic (ECG) examination was conducted in 12 standard conventional leads on electrocardiograph by the Hungarian production Heart Screen 112 D.
Results. The 1st group of the examined patients with reduced LV EF prevails III (significant) degree LA dilatation in 33 (70.21%) cases, II (moderate) degree of LA dilatation was determined in 14 (29.78%), and I (initial) degree was not defined at all. In the 2nd group of the patients with preserved LV EF mainly the II degree of LA dilatation was determined in 44 (44.51%) cases, and decreased LA dilation in 39 (36.79%) cases (p<0.01), and III degree of LA dilation was defined in 23 (21.69%) cases (p<0.01). In patients with stable coronary heart disease, complicated by heart failure with reduced LV EF and II degree of LA dilatation, eNOS levels in the serum was 449.00±39.91 pg/ml, whereas in patients with stable coronary heart disease, complicated by heart failure with preserved LV EF and II stage of LA dilatation – 673.56±50.98 pg/ml (p<0.01). At III stage of LA dilatation in patients of the 1st group level eNOS was 344.20±51.98 pg/ml in the patients of the 2nd group – 616.90±36.49 pg/ml (p<0.01). At the same degree and with LA dilation in the patients of the 2nd group eNOS was 750.27±99.85 pg/ml.
Conclusions. The structural and functional changes of the left atrium and changing factors of vasodilation in patients with stable coronary artery disease of II-III functional classes complicated by heart failure of I-III functional classes are studied. It is established that in the examined patients with stable coronary heart disease complicated by heart failure with reduced left ventricular ejection fraction mainly III (significant) degree of dilatation of the left atrium was determined, while in patients with stable coronary heart disease, complicated by heart failure with preserved left ventricular ejection fraction mainly II (moderate) degree of dilation of the left atrium was determined. In comparison with the results of research among the patients with stable coronary heart disease, complicated by heart failure with reduced left ventricular ejection fraction, and a group of patients with preserved left ventricular ejection fraction, it was determined a significant decrease in eNOS, nitrites, total amount of nitrites and nitrates.
Amosowa K. Clinical Cardiology 1999: 710.
Voronkov L. Primary prevention of heart failure — one of the priorities of modern cardiology. Ukrainian kardіology magazine 2004; 4: 42–47.
Glaser M. Left ventricular hypertrophy and prognosis in patients with chronic heart failure with preserved ejection fraction. Heart Failure 2012; 13: 19–25.
Denesyuk O, Denesyuk V. Dynamics degrees of remodeling and systolic-diastolic left ventricular dysfunction in unstable angina influenced by the optimal long-term treatment. Herald of problems of biology and medicine 2015; 2: 121–126.
Dyuzhykov A, Terentyev V. Features of morpho-functional state of the myocardium in patients with ischemic and no ischemic cardiomyopathy. Modern scientific technology 2007; 12: 23–28.
Zharynova V. Modern Opportunities of opti - mization of endothelium treading therapy in patients with CHF (focus on eNOS). Heart failure 2013; 3: 46–53.
Zakirova AN, Oganov RG, Zakirova NE, Klochkova GR, Musina FS. Myocardial remodeling in ischemic heart disease. Rational Pharmacotherapy in Cardiology 2009; 5(1): 42–45. (In Russ.) DOI:10.20996/18196446-2009-5-1-42-45.
Lang R, Biering M, Devereux RB et al. Recommendations of chambers quantification. Eur J Echocardiogr 2006; 7(2): 79–108.
Mandate of the Ministry of Health of Ukraine from 02.03.2016 №152 On approval of the introduction of medical and technological documents for standardization of care in stable coronary heart disease. News of medicine and pharmacology in Ukraine 2016; 572: 26–60.
Muhorlyamov N. Cardiomyopathy. Medicine 1999: 228.
Oxidative stress in chronic heart failure. The possibilities of pharmacological correction. Y Belenkov, E Privalov, Y Danilogorskaya et al. Cardiology. Cardiovascular Surgery 2009; 1: 4–9.
Patalakh I. Participation of protein C in the regulation of the fibrinolytic capacity of plasma in patients with chronic heart failure. Circulation of blood and hemostasis 2009; 3/4: 95–100.
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implication. Circulation 1990; 81(4):1161–1172.
Recommendations of Association of Cardiologists of Ukraine for the treatment of chronic heart failure in adults (revision 2011). Heart Failure 2011; 1: 101–116.
Aljaroudi W. Inpact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012; 14: 782–788.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure association (HFA) of the ESC. European Heart Journal 2012; 33: 1718–1847.
Ramani GV. Chronic Heart Failure: Contemporary Diagnosis and Management. Mayo Clin. Proc. 2010; 85: 180–195.
Ziuraitiene R, Pangonyte D, Stalioraityte E et al. Cardiomyocyte remodeling in ischemic heart disease. Medicina (Kaunas) 2008; 44: 848–854.
How to Cite
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).